Trial Profile
Phase II study of neoadjuvant gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent external beam radiation with capecitabine for patients with locally advanced unresectable nonmetastatic pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Apr 2012 Planned end date changed from 1 Jan 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov record.
- 09 Dec 2008 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov.